Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDeferred TaxesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Change in Working Capital (2016 - 2025)

Historic Change in Working Capital for Sanofi (SNY) over the last 17 years, with Q4 2025 value amounting to $159.5 million.

  • Sanofi's Change in Working Capital rose 12943.8% to $159.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $322.2 million, marking a year-over-year increase of 11041.4%. This contributed to the annual value of $308.5 million for FY2025, which is 31918.76% up from last year.
  • As of Q4 2025, Sanofi's Change in Working Capital stood at $159.5 million, which was up 12943.8% from $35.1 million recorded in Q3 2025.
  • In the past 5 years, Sanofi's Change in Working Capital registered a high of $1.9 billion during Q2 2024, and its lowest value of -$2.6 billion during Q3 2024.
  • In the last 5 years, Sanofi's Change in Working Capital had a median value of -$33.0 million in 2025 and averaged -$176.5 million.
  • As far as peak fluctuations go, Sanofi's Change in Working Capital skyrocketed by 35390605.18% in 2021, and later crashed by 34325.56% in 2024.
  • Over the past 5 years, Sanofi's Change in Working Capital (Quarter) stood at $1.7 billion in 2021, then tumbled by 128.84% to -$486.7 million in 2022, then surged by 145.77% to $222.7 million in 2023, then crashed by 343.26% to -$541.8 million in 2024, then skyrocketed by 129.44% to $159.5 million in 2025.
  • Its last three reported values are $159.5 million in Q4 2025, $35.1 million for Q3 2025, and $228.7 million during Q2 2025.